BIOGEN INC.
Latest Filing: Apr 29, 2026 • 25 Total Filings
Total Assets
2026
$29.48B
Total Revenue
2026
$2.48B
Net Income
2026
$319.50M
Operating Cash Flow
2026
$645.50M
Filing Year:
2025
Only 2025 data available
Data Source:
Showing data from all document types
Filters:
located incompetes with
BIOGEN INC.
Ticker: BIIB
Unknown Region
1 supplier
Samsung Bioepis Co., Ltd.
contract_manufacturer
Eli Lilly and Company
Oncology (Vectibix vs ERBITUX)
Major Competitor
Legend:
Company
Critical Supplier
Significant Supplier
Standard Supplier
Major Competitor
Emerging Competitor
Competitor
Regional Supplier Concentration
0 regions with known supplier geography · 1 supplier without location data
Risk:LowModerateElevatedHigh
1 supplier · no geography